Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.

[1]  S. Flanagan,et al.  Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid , 2014, Pharmacotherapy.

[2]  Steven D. Dallas,et al.  Treatment Failure and Costs in Patients With Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections: A South Texas Ambulatory Research Network (STARNet) Study , 2013, The Journal of the American Board of Family Medicine.

[3]  D. Talan,et al.  Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. , 2013, The Journal of emergency medicine.

[4]  Anita F. Das,et al.  Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. , 2013, JAMA.

[5]  S. Doron,et al.  Antibiotics for skin infections: new study design and a step toward shorter course therapy. , 2013, JAMA.

[6]  Diane S. Lauderdale,et al.  Epidemics of Community-Associated Methicillin-Resistant Staphylococcus aureus in the United States: A Meta-Analysis , 2013, PloS one.

[7]  T. Fleming,et al.  Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Benjamin A Lipsky,et al.  A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes , 2012, BMC Infectious Diseases.

[9]  M. Grant,et al.  Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. , 2012, International journal of antimicrobial agents.

[10]  K. Bartizal,et al.  In Vitro Activity and Microbiological Efficacy of Tedizolid (TR-700) against Gram-Positive Clinical Isolates from a Phase 2 Study of Oral Tedizolid Phosphate (TR-701) in Patients with Complicated Skin and Skin Structure Infections , 2012, Antimicrobial Agents and Chemotherapy.

[11]  A. Friedrich,et al.  Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. , 2012, International journal of antimicrobial agents.

[12]  M. Zervos,et al.  Epidemiology and Outcomes of Complicated Skin and Soft Tissue Infections in Hospitalized Patients , 2011, Journal of Clinical Microbiology.

[13]  A. Louie,et al.  Impact of Granulocytes on the Antimicrobial Effect of Tedizolid in a Mouse Thigh Infection Model , 2011, Antimicrobial Agents and Chemotherapy.

[14]  R. Corey,et al.  New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  A. Louie,et al.  In Vivo Pharmacodynamics of Torezolid Phosphate (TR-701), a New Oxazolidinone Antibiotic, against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Strains in a Mouse Thigh Infection Model , 2011, Antimicrobial Agents and Chemotherapy.

[16]  G. Corey,et al.  Phase 2, Randomized, Double-Blind, Dose-Ranging Study Evaluating the Safety, Tolerability, Population Pharmacokinetics, and Efficacy of Oral Torezolid Phosphate in Patients with Complicated Skin and Skin Structure Infections , 2010, Antimicrobial Agents and Chemotherapy.

[17]  C. Frei,et al.  Trimethoprim-Sulfamethoxazole or Clindamycin for Community-Associated MRSA (CA-MRSA) Skin Infections , 2010, The Journal of the American Board of Family Medicine.

[18]  P. Viale,et al.  Therapeutic Drug Monitoring of Linezolid: a Retrospective Monocentric Analysis , 2010, Antimicrobial Agents and Chemotherapy.

[19]  J. Bartlett,et al.  Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  G. Zurenko,et al.  In Vitro Activity of TR-700, the Active Ingredient of the Antibacterial Prodrug TR-701, a Novel Oxazolidinone Antibacterial Agent , 2009, Antimicrobial Agents and Chemotherapy.

[21]  J. Finn,et al.  In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains , 2008, Antimicrobial Agents and Chemotherapy.

[22]  G. Oster,et al.  Trends in US Hospital Admissions for Skin and Soft Tissue Infections , 2007, Emerging infectious diseases.

[23]  Patchen Dellinger,et al.  Practice guidelines for the diagnosis and management of skin and soft-tissue infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  R. Nichols,et al.  Clinical presentations of soft-tissue infections and surgical site infections. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  C. Farrington,et al.  Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. , 1990, Statistics in medicine.